The broad long term goal of this project is to understand, on a molecular level, how the p210 bcr/abl protein tyrosine kinase activity ultimately causes a myeloid expansion in chronic phase CML. In order to achieve this objective, it becomes essential to: (a) Identify and characterize the relevant p210bcr/abl substrates, and their interactions, in primary primitive chronic phase CML blasts by immunoprecipitation and immunoblotting with available antibodies to known proteins or by protein purification, sequencing and cloning of, an generation of antibodies to, potential novel proteins; (b) Ascertain the biological functions of the relevant substrates. Ascertain whether the constitutive tyrosine phosphorylation of a substrate in primary primitive chronic phase CML blasts is aberrant or untimely by examining primary primitive and maturing normal subpopulations; (d) Determine the growth factor signal transduction pathways in which the relevant substrates may be involved.
The specific aims of the project are:
Aim 1. To further identify and characterize the relevant p210 bcr/abl substrates and signal transduction pathways affected in primary primitive chronic phase CML blasts: (1a) Characterization of other known relevant substrates; (1c) Further identification of relevant substrates; (id) Identification of P-tyr proteins in kit ligand pathway in primary primitive normal blasts.
Aim 2. To isolate, sequence and characterize p56; (2a) cDNA cloning and sequencing; (2b) Antibody production; (2c) Functional analyses.
Aim 3. To analyze the structure and function of p155, a protein whose tyrosine phosphorylation is elevated in primary CML blasts (3a) Further characterization of p155 in primary chronic phase CML blasts and p210 bcr/abl expressing cell lines; (3b) Purification of p155; (3c) Cloning and sequencing p p155 (ed) Functional analyses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA064593-04
Application #
6237481
Study Section
Project Start
1997-09-15
Project End
1998-05-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Berger, Alice H; Niki, Masaru; Morotti, Alessandro et al. (2010) Identification of DOK genes as lung tumor suppressors. Nat Genet 42:216-23
Rossi, Ferdinand; Yozgat, Yasemin; de Stanchina, Elisa et al. (2010) Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Mol Cancer Res 8:1271-83
Guo, Tianhua; Hajdu, Mihai; Agaram, Narasimhan P et al. (2009) Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res 15:6862-70
Antczak, Christophe; Veach, Darren R; Ramirez, Christina N et al. (2009) Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett 19:6872-6
Kashiwada, Masaki; Cattoretti, Giorgio; McKeag, Lisa et al. (2006) Downstream of tyrosine kinases-1 and Src homology 2-containing inositol 5'-phosphatase are required for regulation of CD4+CD25+ T cell development. J Immunol 176:3958-65
Liang, Xiquan; Hajivandi, Mahbod; Veach, Darren et al. (2006) Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Proteomics 6:4554-64
Janas, Justyna; Skowronski, Jacek; Van Aelst, Linda (2006) Lentiviral delivery of RNAi in hippocampal neurons. Methods Enzymol 406:593-605
Zhao, Mingming; Janas, Justyna A; Niki, Masaru et al. (2006) Dok-1 independently attenuates Ras/mitogen-activated protein kinase and Src/c-myc pathways to inhibit platelet-derived growth factor-induced mitogenesis. Mol Cell Biol 26:2479-89
Oki, Shinji; Limnander, Andre; Yao, Pin Mei et al. (2005) Dok1 and SHIP act as negative regulators of v-Abl-induced pre-B cell transformation, proliferation and Ras/Erk activation. Cell Cycle 4:310-4
Wolff, Nicholas C; Veach, Darren R; Tong, William P et al. (2005) PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood 105:3995-4003

Showing the most recent 10 out of 37 publications